Aims: Fremanezumab is a fully humanized IgG 2 Δa/κ monoclonal antibody specific for calcitonin gene-related peptide developed and approved for the preventive treatment of migraine in adults. The population pharmacokinetics (PK) of fremanezumab were characterized in healthy subjects and patients with chronic migraine and episodic migraine, including the effects of intrinsic and extrinsic factors on PK variability.
| INTRODUCTION
Calcitonin gene-related protein (CGRP) is a well-studied neuropeptide and vasodilator that plays an important role in the pathogenesis of migraine, both centrally and peripherally. 1, 2 Increased CGRP levels have been detected in the external jugular vein during an acute migraine attack, 3 consistent with previous reports that intravenous (IV) CGRP administration induces migraine-like headaches in most individuals with migraine, but not healthy control subjects. 4 Small molecule CGRP receptor antagonists have demonstrated efficacy in acute migraine [5] [6] [7] and monoclonal antibodies (mAbs) that target CGRP or its receptor have demonstrated efficacy as preventive treatment in episodic migraine (EM) and chronic migraine (CM) studies. 8, 9 Fremanezumab, a fully humanized IgG 2 Δa/κ mAb, selectively targets CGRP and has been approved by the US Food and Drug Administration for the preventive treatment of migraine in adults. 8 Fremanezumab binds to the CGRP ligand and blocks both the αand β-CGRP isoforms from binding to the CGRP receptor. 8 Introduction of 2 mutations into the constant region of the fremanezumab heavy chain limits antibody effector functions, thereby preventing fremanezumab from stimulating antibody-dependent cell-mediated cytotoxicity and triggering complement-mediated lysis. 10 During the development of fremanezumab, pharmacometric modelling and simulation were used extensively to support development-related decision-making and are described in this manuscript. A population pharmacokinetic (PopPK) model was iteratively developed using a 3-staged approach. Initially, it was developed using intensive data from healthy subjects in 2 phase 1 studies following IV and subcutaneous (SC) administration, 11 then adding informative data from the long-term safety (LTS) phase 3 study in EM and CM migraine patients after SC administration. 12 Finally, it was further refined by adding trough samples collected after SC administration from 2 phase 2b [13] [14] [15] and 3 phase 3 trials (2 pivotal studies and the LTS study. 12, 16, 17 The final PopPK model provided a basis for prediction of subject-specific exposure estimates to support future assessment of exposureresponse relationships for efficacy and safety endpoints. This manuscript represents the first published PopPK analysis for a therapeutic mAb targeting the CGRP pathway.
| METHODS

| Data
Data from 7 clinical studies evaluating IV and SC administration of fremanezumab in healthy subjects and patients with EM or CM were pooled for analysis ( Table 1 ). The 2 phase 1 studies included full-profile blood sampling for determination of fremanezumab concentrations over 90 or 225 days, whereas a sparse sampling strategy (monthly predose trough samples) was implemented in the phase 2b and 3 studies (2 pivotal studies and 1 LTS study). Two additional nontrough samples were obtained from patients enrolled in the phase 3 LTS study who did not roll over from 1 of the 2 double-blind phase 3 trials.
Fremanezumab was administered subcutaneously, except for 1 phase 1 study that included both IV and SC administration.
All studies were conducted in accordance with the principles of the Declaration of Helsinki. Clinical protocols were reviewed and approved for each site by institutional review boards and all study participants provided written informed consent prior to enrolment in the studies.
| Bioanalysis
A sandwich enzyme-linked immunosorbent assay procedure was used for measurement of plasma fremanezumab concentrations. The method was validated in the concentration range of 250 to 3500 ng/mL as assessed via accuracy and precision using fremanezumab spiked at different levels in the human plasma samples.
The accuracy of the spiked samples varied between 98 and 104% of the nominal concentrations. The interassay precision varied from 3 to 7% and the intra-assay from 3 to 5%. The lower limit of quantitation (LLOQ) value for the PK assay used in the analysis was 250 ng/mL.
| Population PK modelling
NONMEM, v7.3, was used for all model development (first-order conditional estimation with interaction method), simulations and evaluation procedures, 18 and KIWI, v3 (or later), was used for model discrimination and data visualization. 19 What is already known about this subject • Fremanezumab plasma concentration-time profiles and exposure parameters were similar in Japanese and Caucasian healthy subjects following single dose subcutaneous administration of 225, 675 and 900 mg.
• The long half-life of fremanezumab (30 days) supports monthly or quarterly administration.
What this study adds
• The population pharmacokinetics of fremanezumab after intravenous and subcutaneous administration was characterized in over 2500 subjects (including patients with chronic migraine or episodic migraine) using a 2compartment model with first-order absorption and elimination.
• Weight was the only significant covariate predictive of variability in fremanezumab pharmacokinetics; higher weight was associated with lower exposure. Between-subject variability (BSV) in parameters was modelled using an exponential form. Residual variability (RV) was modelled using a proportional or additive plus proportional form, as appropriate. 20
| Covariate analysis
The influence of various intrinsic and extrinsic factors on the PK of fremanezumab was evaluated, including weight, age, race, sex, patient status, albumin, anti-drug antibody (ADA) status, injection site, renal function category, hepatic function category, and use of preventive, acute or analgesic medications. Continuous covariates were centred about the population median value to improve the precision of the parameter estimates. 20 Forward selection followed by backward elimination (α = 0.01 with decrease in BSV by ≥5% and α = 0.001, respectively; 1 df for χ 2 -distribution) methods were used to assess covariate relationships. After backward elimination, the reduced multivariable model was then evaluated for any remaining biases in the BSV and RV error models and refined, as necessary.
| Model evaluation
The adequacy of the final model was evaluated using a simulationbased, prediction-corrected visual predictive check (VPC) method. 21, 22 Simulations were performed (n = 1000 replicates) using the final model and statistics of interest were calculated for comparison with observed data; e.g., the 5th, 50th (median) and 95th percentiles of the simulated and observed concentration distributions. These percentiles were plotted vs time, with the original observed dataset and percentiles based on the observed data overlaid to visually assess concordance between the model-based simulated data and the observed data. Table S1 provides a summary of the intrinsic and extrinsic factors by study phase. to have approximately 29% lower and 45% higher CL and 40% lower and 71% higher V c , respectively. The final model structure illustrates how the iterative approach maximized the use of informative data during model development to address the apparent discrepancy in compartmental structure for IV vs SC dosing. Exploratory plots demonstrated that the concentration-time profile following SC administration reflects a monophasic decrease after absorption, while the profile following IV administration reflects a biphasic process. In fact, when data following IV administration were not included in the dataset, the 2-compartment model fit could not be supported. 23 By fixing the parameters defining the peripheral compartment, both the IV and SC data were fit adequately and a precise estimate of bioavailability was obtained. Given that the apparent differences in fremanezumab elimination between IV and SC administration are probably due to the fact that the relatively slow absorption phase following SC administration masks the initial elimination phase observed following IV administration, rather than patientrelated differences, if IV data were available from patients with migraine (EM or CM), it would be expected that the estimates of Q and V p would be similar to those observed in healthy volunteers. Furthermore, the effect of patient status, defined as healthy subjects vs patients with migraine, was evaluated as a covariate and found not to be a statistically significant predictor of variability in fremanezumab PK (see also Supporting Figure S2 illustrating the similarity in exposure between healthy subjects and patients).
| Simulations
| Final fremanezumab population PK model
| Simulations
In general, fixed and random effect parameters were estimated with good precision, and goodness-of-fit plots, as well as VPC diag- As generally observed with mAbs, weight was a significant predictor of variability in PK for both CL and V c ; higher weight was associated with increased CL and V c . The effects of other covariates evaluated (race, sex, albumin, age, renal function category, injection site, and acute, analgesic and preventive medications) were not found to statistically significantly influence the PK of fremanezumab. The lack of race as a significant covariate is consistent with a previous noncompartmental PK analysis comparing the single-dose PK of fremanezumab in Japanese and matched Caucasian healthy subjects. 11 Geometric mean ratios (i.e. Japanese/Caucasian ratios) for AUC and Although it is reported that injection site can have an impact on both the rate and the extent of absorption for mAbs, the effect of injection site on the extent of absorption is considered less likely. 26, 27 Furthermore, since the lymphatic pathway may represent the primary mechanism for absorption of IgG-type mAbs, it is possible that the inherent slow absorption makes the regional variation of lymph flow associated with different injection sites negligible in terms of an effect on F such that the extent of absorption does not differ significantly between dosing sites. 28 Based on the model, fremanezumab exhibits linear, dose-proportional kinetics with a calculated median terminal half-life of approximately 30 days with fremanezumab concentrations approaching steady state by 3 months of treatment and steady-state conditions are expected to be achieved by approximately 168 days (6 months) for the 225 mg SC monthly and 675 mg SC quarterly dosing regimens.
This estimated half-life is consistent with the typical range of half-life values reported for other therapeutic mAbs. 29, 30 In particular, for the mAbs that target the CGRP pathway, the reported half-life is 28 days for erenumab and 27 days for galcanezumab. 31, 32 Approximately 2fold accumulation based on AUC 0-28 and C max is anticipated for the 225 mg SC once-monthly dosing regimen, whereas, minimal accumulation is anticipated for the 675 mg SC once-quarterly fremanezumab dosing regimen.
In conclusion, the PopPK model for fremanezumab well described the PK data observed in a large population of healthy subjects and patients with CM or EM following IV and SC administration of a wide range of doses and dosing intervals. As expected, this analysis confirmed the influence of weight on the PK parameters of fremanezumab, whereby higher body weight is associated with lower exposure. The prolonged absorption and long elimination half-lives for fremanezumab supports the use of monthly or quarterly dosing regimens and the lack of significant influence of other intrinsic or extrinsic factors on fremanezumab exposure suggests no need for dose modification in special populations. Furthermore, the predictive performance of the model indicates its appropriateness in predicting subject-specific estimates of exposure for use in the evaluation of relationships between exposure and safety and efficacy response.
